Text Size

A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma

This study has been withdrawn prior to enrollment.
(could not find subject population)
Sponsor:
Information provided by:
Bernstein Clinical Research Center
ClinicalTrials.gov Identifier:
NCT00242359
First received: October 17, 2005
Last updated: January 27, 2009
Last verified: January 2009
History of Changes
  Purpose

Management of animal induced occupational asthma is mainly avoidance, but this is not feasible for many occupations. Treatment with avoidance and conventional treatment is also not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and may be effective at reducing symptoms and disease progression in the animal handlers population.


Condition Intervention Phase
Allergy Induced Asthma
 Drug: omalizumab
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma

Resource links provided by NLM:

MedlinePlus related topics: Allergy Asthma
Drug Information available for: Omalizumab
U.S. FDA Resources

Further study details as provided by Bernstein Clinical Research Center:

Estimated Enrollment: 16
Study Start Date: November 2005
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. ages 18-65
  2. occupation that involves close contact with animals
  3. stable dose of ICS for 30 days
  4. Skin test positive to one or more animals
  5. evidence of asthma on spirometry
  6. demonstrate PEFR variability-

Exclusion Criteria:

  1. on allergen immunotherapy
  2. on prohibited medications
  3. unstable asthma
  4. recent URI
  5. known hypersensitivity to omalizumab-
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Jonathan A. Bernstein, MD, Bernstein Clinical Research Cente
ClinicalTrials.gov Identifier: NCT00242359     History of Changes
Other Study ID Numbers: 2085
Study First Received: October 17, 2005
Last Updated: January 27, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
 Immune System Diseases
Omalizumab
Anti-Allergic Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on May 16, 2013